UNSPSC 51271908: Chloroprocaine

This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5YVB0POT2H, chemically known as benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester but generally known as chloroprocaine, which bears US NIH Compound Identifier 8612. European Medicines Agency schedules Chloroprocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06193MIG.

UNSPSC 51271908 Chloroprocaine, a Commodity code, encompasses local anesthetic pharmaceutical products that state and local governments procure for healthcare delivery across hospitals, clinics, emergency services, and correctional facilities. The scope of work involves supplying active pharmaceutical ingredients and finished formulations meeting current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, with vendors required to maintain comprehensive product documentation including National Drug Codes (NDC), strength, dosage form, packaging configurations, and manufacturing locations. State and local issuing bodies soliciting under this code include multistate cooperative purchasing alliances administering on behalf of multiple state agencies and their subordinate healthcare systems, as well as individual state departments of health and administration. Vendors must establish contractual relationships with authorized pharmaceutical wholesalers and maintain pricing flexibility across multiple formats (flat price, net price, WAC-minus structures) while demonstrating robust insurance coverage, reliable supply chains, and compliance with FDA requirements and product shelf-life standards.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement on behalf of participating states including Oregon, issued RFP S1070000015802 in January 2026 seeking manufacturers of generic multi-source pharmaceuticals and OTC products for statewide and regional distribution. Proposals were due March 26, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and 5 percent each on administrative compliance, EDI capability, and administrative fee acceptance. MMCAP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with products available by May 15, 2026 and resulting contracts effective July 1, 2026. The contract term is two years for new responders with optional extensions at MMCAP's discretion, and vendors must comply with a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation.